BioNTech stock has had a tough run over the past few years and the valuation checks now lean expensive, so the current price raises questions about how much of the recovery story is already reflected ...
Source LinkBioNTech stock has had a tough run over the past few years and the valuation checks now lean expensive, so the current price raises questions about how much of the recovery story is already reflected ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.